Confirmed 2020 Partners:


Program Partner: BPM

Bio Preventive Medicine Corporation (BPM) is a clinical-staged biotech company. BPM has been focused on translating validated and IP-protected biomarkers into diagnostic solutions for unmet clinical needs, especially in DKD and non-proteinuric renal disease. Our first product, DNlite, is a non-invasive urinary test for predicting/monitoring the progression of Diabetic Kidney Disease (DKD). We can help partners in the development of drugs not only for evaluating renal efficacy but also renal safety.



Exhibition Partner: Frenova

Frenova is the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research and its adjacent conditions. As a Fresenius Medical Care North America company, Frenova manages clinical research assets and resources including over 450 principal investigators at more than 260 sites representing 160 medical practices. Frenova’s F1RST Up® network of select investigative sites provides sponsors with accelerated study startup, while Frenova’s SMO manages clinical research staff and streamlines trial operations to help investigators enroll more patients and perform more studies.



Exhibition Partner: Gubra

Gubra is a privately held biotech located in Denmark delivering scientific counselling, contract research services, and projects for co-development in five main areas: Obesity, diabetes, NASH, kidney, and heart diseases. Gubra experts cover pre-clinical disciplines such as in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS, bioinformatics and ex vivo assays. Gubra has a hybrid business model with a pipeline of early target and drug discovery programs aimed for partnering while also delivering preclinical services to customers.


DiscoveryBioMed-Logo (high-res)

Event Partner: DiscoveryBioMed

DiscoveryBioMed, Inc. (DBM) is a boutique R&D and CRO biotechnology company that leverages human cell platform technologies for drug discovery and validation in renal, respiratory, and metabolic therapeutic areas. DBM currently offers highly advanced 3D human cell based in vitro cyst forming models of Polycystic Kidney Disease (PKD) with development underway for a similar system for Chronic Kidney Disease (CKD). To learn more, visit our website or contact for inquiries about available services.